Join us at the Virtual Week 2020 organized by UEG (United European Gastroenterology) from October 11th to 13th and discover our last clinical results which reinforce the high efficacy of IbSium® to alleviate gastrointestinal symptoms and improve the quality of life.
“Saccharomyces cerevisiae CNCM I-3856 in IBS predominant constipation: a randomized, double-blind, placebo-controlled, multicenter clinical trial” is the title of the poster that will be held by Arnaud Bourreille, Gastroenterologist at the Institute for Digestive Tract Diseases, (Nantes-France).
IbSium® is our unique and patented probiotic yeast S. cerevisiae CNCM I-3856. Do not miss the opportunity to learn more about one of the most documented probiotic for a daily and complete digestive comfort.
